The majority of IRRs in the phase 3 TRAILBLAZER-ALZ 2 study

• occurred within the first 4 doses of donanemab (70%), and
• typically occur during infusion or within 30 minutes postinfusion.1

Infusion reactions and hypersensitivity reactions were reported more than 24 hours after a donanemab infusion in 5.5% of donanemab-treated participants.4

Signs and symptoms of IRRs include

• chills
• erythema
• nausea/vomiting
• difficulty breathing/dyspnea
• sweating
• elevated blood pressure
• headache
• chest pain, and
• low blood pressure.1
  

In the event of an IRR, the infusion 

• rate may be reduced, or
• may be discontinued.1

Initiate appropriate therapy as clinically indicated.1 

Pretreatment with antihistamines, acetaminophen, or corticosteroids prior to subsequent dosing may be considered.1 

Donanemab is contraindicated in patients with known serious hypersensitivity to donanemab or to any of the excipients.1 

Hypersensitivity reactions, including anaphylaxis and angioedema, have occurred in patients who were treated with donanemab.1

Promptly discontinue the infusion upon the first observation of any signs or symptoms consistent with a hypersensitivity reaction and initiate appropriate therapy.1